ReviewCold Spring Harbor perspectives in medicine2014
Synthetic chemically modified mRNA (modRNA): toward a new technology platform for cardiovascular biology and medicine.
Review in Cold Spring Harbor perspectives in medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 64 citations in OpenAlex.
- Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Trial
- A pH‑responsive hydrogel delivering ISOC1 modRNA attenuates disc degeneration by promoting BIRC6‑mediated MYC degradation and inhibiting SBSN expression.Journal of nanobiotechnology · 2026Article
- Targeted Delivery of mRNA to the Heart via Extracellular Vesicles or Lipid Nanoparticles.Journal of extracellular vesicles · 2026Article
- Messenger RNA therapy in bone and joint diseases: Rationale, delivery systems, and applications.Biomaterials translational · 2026Article
- Review
- Optimizing rhBMP-2 Therapy for Bone Regeneration: From Safety Concerns to Biomaterial-Guided Delivery Systems.International journal of molecular sciences · 2025Review
- Rapid generation of functional vascular organoids via simultaneous transcription factor activation of endothelial and mural lineages.Cell stem cell · 2025Article
- Implementing BMP-7 Chemically Modified RNA for Bone Regeneration with 3D Printable Hyaluronic Acid-Collagen Granular Gels.Advanced healthcare materials · 2025Article
- Transcriptional activation of regenerative hematopoiesis via microenvironmental sensing.Nature immunology · 2025Article
- Human adipose-derived multipotent stromal cells enriched with IL-10 modRNA improve diabetic wound healing: Trigger the macrophage phenotype shift.Bioengineering & translational medicine · 2025Article
- RNA Therapeutics: Bridging Discovery and Clinical Implementation.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Endovascular transplantation of mRNA-enhanced mesenchymal stromal cells results in superior therapeutic protein expression in swine heart.Molecular therapy. Methods & clinical development · 2024Article
- Next-generation direct reprogramming.Frontiers in cell and developmental biology · 2024Review
- Placental growth factor exerts a dual function for cardiomyogenesis and vasculogenesis during heart development.Nature communications · 2023Article
- Article
- Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- Modified mRNA Therapeutics for Heart Diseases.International journal of molecular sciences · 2022Review
- Unlocking the promise of mRNA therapeutics.Nature biotechnology · 2022Review
- Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- Progress in Bioengineering Strategies for Heart Regenerative Medicine.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past two decades, a host of new molecular pathways have been uncovered that guide mammalian heart development and disease. The ability to genetically manipulate these pathways in vivo have largely been dependent on the generation of genetically engineered mouse model systems or the transfer of exogenous genes in a variety of DNA vectors (plasmid, adenoviral, adeno-associated viruses, antisense oligonucleotides, etc.). Recently, a new approach to manipulate the gene program of the adult mammalian heart has been reported that will quickly allow the high-efficiency expression of virtually any protein in the intact heart of mouse, rat, porcine, nonhuman primate, and human heart cells via the generation of chemically modified mRNA (modRNA). The technology platform has important implications for delineating the specific paracrine cues that drive human cardiogenesis, and the pathways that might trigger heart regeneration via the rapid generation of modRNA libraries of paracrine factors for direct in vivo administration. In addition, the strategy can be extended to a variety of other cardiovascular tissues and solid organs across multiple species, and recent improvements in the core technology have supported moving toward the first human studies of modRNA in the next 2 years. These recent advances are reviewed along with projections of the potential impact of the technology for a host of other biomedical problems in the cardiovascular system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.